Text Size

Breath Analysis by Ion Mobility Spectrometry

This study is currently recruiting participants.
Verified May 2011 by Lung Clinic Hemer
Sponsor:
Information provided by:
Lung Clinic Hemer
ClinicalTrials.gov Identifier:
NCT00632307
First received: February 29, 2008
Last updated: June 22, 2011
Last verified: May 2011
History of Changes
  Purpose

Recognition of disease specific clusters of volatile organic compounds in patients with different lung diseases, using breath analysis with ion mobility spectrometry. Lung diseases of interest are:

  • COPD
  • tumors
  • airway infection
  • interstitial lung disease
  • sleep apnea Hypothesis: Breath analysis with ion mobility spectrometry can differentiate pulmonary disorders.

Condition
Lung Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Lung Clinic Hemer:

Biospecimen Retention:   Samples Without DNA

breath, pleural fluid (only in patients with therapeutic pleurocentesis)


Estimated Enrollment: 1000
Study Start Date: July 2006
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
COPD
2
lung cancer
3
airway infection
4
interstitial lung disease
5
sleep apnea
6
pulmonary disorders with pleural infusions
7
sarcoidosis
8
healthy persons

Detailed Description:

Recruitment of patients with different lung diseases goes on. First sub-group analysis of patients with COPD,lung cancer and sarcoidosis is done in order to create a training set of VOC-clusters for further validation in a bigger population of patients.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients of the lung clinic hemer

Criteria

Inclusion Criteria:

  • Any patient
  • Ages 18-90 years old
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00632307

Contacts
Contact: Michael Westhoff, MD 004923729082203 michael.westhoff@lkhemer.de
Contact: Patric Litterst, MD 004923729082545 pneumologie@lkhemer.de

Locations
Germany
Lung Clinic Hemer Recruiting
Hemer, Germany, 58675
Contact: Michael Westhoff, MD     004923729082203     michael.westhoff@lkhemer.de    
Contact: Patric Litterst, MD     004923739082545     pneumologie@lkhemer.de    
Principal Investigator: Michael Westhoff, MD            
Sponsors and Collaborators
Lung Clinic Hemer
Investigators
Principal Investigator: Michael Westhoff, MD Lung Clinic Hemer, 58675 Hemer, Germany
  More Information

Publications:
Bunkowski,A, Bödeker B, Bader S, Westhoff M, Litterst P, Baumbauch JI.Signals in human breath related to Sarcoidosis. — Results of a feasibility study using MCC/IMS. Int. J. Ion Mobil. Spec. (2009) 12:73-79

Responsible Party: Michael Westhoff MD, Lung Clinic Hemer
ClinicalTrials.gov Identifier: NCT00632307     History of Changes
Other Study ID Numbers: lkhemer1-2008
Study First Received: February 29, 2008
Last Updated: June 22, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Lung Clinic Hemer:
lung tumor
pleural tumor
interstitial lung disease
airway infection
 COPD
sleep apnea
ion mobility spectrometry
breath analysis

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 21, 2013